Kiniksa Pharmaceuticals International, plc develops and commercializes novel therapies for diseases with unmet need, with a focus on cardiovascular indications. News about Kiniksa commonly covers ARCALYST (rilonacept), an IL-1α and IL-1β cytokine trap approved by the FDA for recurrent pericarditis and other autoinflammatory indications.
Company updates also address ARCALYST commercial performance, patient-awareness initiatives in recurrent pericarditis, quarterly and annual financial results, and portfolio execution. Additional recurring themes include the KPL-387 recurrent pericarditis program, KPL-1161 IL-1 receptor antagonist development, corporate updates, and healthcare conference presentations.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Kiniksa Pharmaceuticals reported Q4 2022 net product revenue of ARCALYST at $39.9 million and full-year revenue of $122.5 million. For 2023, net product revenue is expected between $190 million and $205 million, indicating over 60% growth from 2022. The average therapy duration was approximately 18 months, with a strong payer approval rate exceeding 90%. Kiniksa maintains cash reserves to support operations through at least 2025. Financially, total revenue for 2022 reached $220.2 million with a net income of $183.4 million, boosted by a significant tax benefit.
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) will host a conference call on February 28, 2023, at 8:30 a.m. ET, to discuss its fourth quarter and full-year 2022 financial results and recent portfolio execution.
The call will be accessible via a live webcast on Kiniksa's website. Telephone participants must register to receive dial-in details. A replay will be available approximately 48 hours post-event. Kiniksa focuses on developing therapeutic medicines for critical unmet medical needs, with assets like ARCALYST and KPL-404 targeting cardiovascular and autoimmune conditions.